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Abstract
Nanoparticles have been extensively developed for therapeutic and diagnostic applications. While the focus of nanoparticle
trafficking in vivo has traditionally been on drug delivery and organ-level biodistribution and clearance, recent work in
cancer biology and infectious disease suggests that targeting different cells within a given organ can substantially affect the
quality of the immunological response. Here, we examine the cell-level biodistribution kinetics after administering ultrasmall
Pluronic-stabilized poly(propylene sulfide) nanoparticles in the mouse. These nanoparticles depend on lymphatic drainage
to reach the lymph nodes and blood, and then enter the spleen rather than the liver, where they interact with monocytes,
macrophages and myeloid dendritic cells. They were more readily taken up into lymphatics after intradermal (i.d.) compared
to intramuscular administration, leading to ,50% increased bioavailability in blood. When administered i.d., their
distribution favored antigen-presenting cells, with especially strong targeting to myeloid cells. In tumor-bearing mice, the
monocytic and the polymorphonuclear myeloid-derived suppressor cell compartments were efficiently and preferentially
targeted, rendering this nanoparticulate formulation potentially useful for reversing the highly suppressive activity of these
cells in the tumor stroma.
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Introduction
Nanosized particles have found various applications, such as in
drug delivery [1], in vivo imaging contrast agents [2], and in vaccina-
tion [3]. Nanoparticulate drug formulations can behave differently
from their soluble counterparts due to size-dependent lymphatic
drainage and uptake pathways [4]. Their tunable parameters,
including size as well as core and surface chemistries, may be
tailored to fit a desired application, and they can further be modified
with bioactive ligands, such as antibody fragments or homing
peptides, to enhance their targeting capabilities [1,5,6]. Such plat-
forms exploit the specificity of the covalently bound ligands to carry
their payload to target cells and tissues for therapeutic or diagnostic
applications [7]. Such applications span from simple passive carriers
and solubilizers for hydrophobic drugs, such as chemotherapeutics,
to even more complex systems that specifically trigger immune
responses for vaccines [8–11]. In all of these applications, the
distribution of nanoparticles after administration is an important
question, including understanding toxicity concerns [12].
We and others have previously shown that by exploiting lym-
phatic drainage, sub-100 nm particles drain freely to the lymph
nodes (LNs) after injection in lymphovascularized tissues such as
the dermis [10,13]; the nanoparticles are sufficiently small as to not
be entrapped in the network structure of the tissue interstitium,
and the interstitial flow convects them into the draining lymphatic
vessels. Exploiting size permits local LN targeting without the use
of specific targeting ligands [14] or direct injection into LNs [15].
In the LN, the nanoparticles are rapidly taken up by antigen
presenting cells (APCs) and can therefore be used to modulate
immune responses [10,16,17].
In nature, viruses range in size from ,25 to 200 nm and traffic
to the draining LN [18] where, depending on their glycosylation
pattern and targeting of specific cell subsets [19], they are
transported to the blood, spleen and liver to elicit different
immunological outcomes. Similarly, vaccine delivery platforms
[3,10] are often engineered to be in this size range, because
draining LNs can guide the lymph to cell specific compartments
[20]. As nanosized particulates engage the same entrance and
clearance mechanisms as viruses [3], and as the cell type these
agents first encounter has an impact on infectious and immuno-
logical outcomes [18], we were motivated to investigate the exact
cellular distribution followed by the fully synthetic Pluronic-
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stabilized poly(propylene sulfide) (PPS) nanoparticles (NPs, using
this abbreviation to refer only to these specific nanoparticles) that
we have previously described and used as a vaccine platform [8–
10,16,21].
Materials and Methods
Mice
C57Bl/6 female mice, 6–8 wks old, were purchased from Harlan
Laboratories (Gannat, France). K14-VEGFR-3-Ig transgenic mice
[22], which lack dermal lymphatic drainage, were a kind gift of Dr.
Kari Alitalo (University of Helsinki, Finland). All experiments were
performed with the permission of the Veterinary Authority of the
Canton de Vaud, Switzerland. Immunizations were performed
under isofluorane.
Ethics statement
All mouse procedures and manipulations were conducted
according to the ethical principles and guidelines for housing
and experiments on animals of the Swiss federal veterinary office.
The animal protocol (protocol number 2235) describing the
procedures was reviewed and approved by the veterinary affair
office of the canton of Vaud, Switzerland.
Chemicals, reagents and antibodies
All chemicals were reagent grade and purchased from Sigma-
Aldrich (Saint Louis, MO) unless otherwise noted. Antibodies for
flow cytometry were purchased from eBioscience (San Diego, CA)
and BioLegend (San Diego, CA) unless otherwise noted. Cell
viability was determined using either propidium iodide (PI) or
Live/Dead cell dyes (Invitrogen, Zug, Switzerland). For intracel-
lular staining, cells were fixed and permeabilized using BD
Cytofix/Cytoperm Fixation/Permeabilization Solution Kit (BD
Biosciences, San Jose, CA). Secondary antibodies for immunoflu-
orescence were from Invitrogen.
Nanoparticle synthesis
Pluronic-stabilized poly(propylene sulfide) nanoparticles (referred
to herein simply as NPs) were synthesized as previously described
[23]. Briefly, 5.07 mmol of propylene sulfide (400 mL) was
emulsified in 5% (w/v) Pluronic F127 (500 mg) in 10 mL of
ddH2O. In-house synthesized four-arm initiator (40.2 mmol,
14.8 mg) was used to start the polymerization of propylene sulfide.
After dialyzing for 48 h, 2 mL of NPs (30 mg/mL) were
fluorescently labeled with 0.048 mM (0.05 mg) of Dy649-maleimide
(NP-Dy649) maleimide (Dyomics GmbH, Jena, Germany) in
phosphate buffered saline (PBS) at RT for 24 h, followed by gel
filtration in a Sepharose CL6B size exclusion gravity column with
PBS (150 mM) as eluent [23] or dialyzed against 0.9% NaCl.
Fractions containing the most fluorescent NPs were pooled together.
The presence of free dye was assessed by size exclusion HPLC
chromatography (Figure S1). NP biotinylation was accomplished by
reacting derivatized Pluronic F127 carboxyl [23] with 5 equivalents
of N-(+)-Biotinyl-3-aminopropylammonium trifluoroacetate salt
and 10 eq. of N-hydroxysuccinimide and 1-Ethyl-3-(3-dimethyla-
minopropyl) carbodiimide overnight. Biotinylated NPs were
dialyzed prior to use.
Virosome production
To produce a fluorescent lipid (L-a-phosphatidylethanolamine-
Dy649), 200 nmol L-a-phosphatidylethanolamine (Avanti Polar
Lipids, Birmingham, AL) was added to 200 nmol Dy649-NHS
(Dyomics GmbH, Jena, Germany) in 200 mL methanol, and the
reaction was carried out in the dark, under argon gas, at room
temperature. After 40 min, 3.3 nmol of triethylamine were added,
and the reaction was terminated after 80 min. The reaction
product and free dye were separated by TLC as above, and re-
extracted with methanol; the yield of the coupling reaction at this
point was 36.6% (as determined by absorption at 649 nm).
Preparative full-scale HPTLC of the reaction product followed by
repeated (36) recrystallization from methanol yielded 17.8 nmol
of L-a-phosphatidylethanolamine-Dy649 as determined by phos-
phate analysis.
Approximately 5 mg of A/Singapore/6/86 influenza virus
(1.5 mmol of membrane phospholipid) was inactivated by 0.05%
beta-propiolactone (Molekula, Dorset, UK) overnight at 4uC,
pelleted by centrifugation, and dissolved in 1,2-dicaproyl-s-n-
phosphatidylcholine (DCPC; Avanti Polar Lipids, Birmingham,
AL); the nucleocapsid was then removed by centrifugation. To the
supernatant, 750 nmol of phospholipid 22.5 nmol of L-a-phos-
phatidylethanolamine-Dy649, dissolved in 100 mM DCPC in
HNE buffer (145 mM NaCl, 5 mM HEPES, 1 mM EDTA), was
added. The resulting mixture was sterilized by filtration through
0.22 mm, and dialyzed extensively against HNE in gamma-
irradiated slide-a-lyzers (Pierce, Rockford, IL US, 30 kD MW
cut-off).
Particle characterization
Fluorescence Characterization. Fluorescence intensity was
normalized by taking a known weight of NPs and measuring the
particle suspension fluorescence using a plate spectrometer (Saphire,
Tecan Group Ltd., Ma¨nnedorf, Switzerland).
Endotoxin Characterization. All of the evaluated formula-
tions were tested for endotoxin levels prior to use (,0.01 EU/mg)
utilizing the TLR4 HEK Blue system (Invivogen, Carlsbad, CA US)
using an LPS standard (Sigma-Aldrich, Taufkirchen, Germany).
Size Characterization. NP size measurements were ob-
tained by dynamic light scattering (DLS) on a Nano ZS Zetasizer
instrument (Malvern Instruments, Malvern, UK) with a 632 nm
laser using PMMA cuvettes. NP solutions were diluted with PBS
(150 mM pH 7.4) to a final NP concentration of 2 mg/mL before
measurement. Particle sizes (in nm) were obtained as the Z-
average by fitting the correlation function using the cumulant
method. Dy649-labeled particles were measured in dilute disper-
sions on a Brookhaven goniometer system (Brookhaven Ltd,
Worcestershire, UK) using an Lexel-Laser argon laser light source
operating at a wavelength of 488 nm at a fixed detector angle of
90uC. Fluorescence of NP and VS were normalized by their
fluorescence of Dy649 in the presence of 0.1% Triton X100, as
measured in a fluorescence plate reader.
Bioavailability study
Mice were administered either 1.8 mg of NP-Dy649 (15 mg/mL)
intravenously (i.v.), or 450 mg in each footpad i.d. or intramuscularly
(i.m.). At various timepoints (10 min, 1 h, 6 h, 12 h, 24 h, 48 h,
96 h and 144 h), 5 mL of blood was withdrawn from the tail and
immediately diluted 406 in HBSS (pH = 7.4). The fluorescence of
blood samples was measured in a plate reader (excitation 655 nm,
emission 676 nm) and correlated with a standard curve of NP-
Dy649 in whole blood. Bioavailability F was determined according
to the following ratio: F~
AUC½ X :doseiv
AUC½ X :doseX
, where AUC is the area
under the curve and X is i.d. or i.m., respectively.
Nanoparticle Cellular Distribution
Mice were inoculated with 450 mg (15 mg/mL) of NP-Dy649
per footpad. Blood was drawn from each mouse and leukocytes
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were isolated using a 60% Percoll step gradient after 20 min
centrifugation at 8006g at room temperature. Organs (the lungs,
liver, kidneys, skin draining LNs and spleen) were harvested after
transcardial perfusion with PBS. Tissue was gently dissociated and
incubated in Collagenase D (Roche Ltd., Mannhein, Germany) for
45 min at 37uC and 5% CO2. Single-cell suspensions were acquired
after passing the digested organs through a 70 mm strainer. Lungs,
liver, and kidneys leukocytes were isolated using a 40%, 70% Percoll
step gradient as described above. Cells were stained with the
following panels: (1) I/Ab-FITC, F4/80-PE, CD11b-PerCP5.5,
CD11c-Pacific Blue, CD8a-eFluor750, GR-1 biotin and streptavidin
Pacific Orange, and (2) CD25-FITC, TCRcd-PE, B220-PerCP5.5,
CD4-PeCy7, CD3e-Pacific Blue, CD8a-eFluor750, CD45-biotin &
streptavidin Pacific Orange. Flow cytometry was performed with a
CyAn ADP analyzer (Beckman Coulter, Nyon, Switzerland).
Intradermal versus intramuscular administration
Mice were administered with 450 mg (15 mg/mL) of NP-Dy649
per limb, injected i.d. or i.m.. After 1, 6, 12, 24 or 144 h, LNs and
spleens were harvested. As above, tissue was processed to single
cell suspensions, stained, and analyzed by flow cytometry.
Immunofluorescence
Organs were harvested and immediately frozen in Tissue-TekH
O.C.T. Compound (Sakura, Torrence, CA) in isopentane and
liquid N2, and sectioned at 9 mm (LNs) or 40 mm (spleens).
Sections were post-fixed in acetone at 220uC. LN sections were
either stained for hematoxylin and eosin, or immunostained for (i)
CD35 (biotinylated rabbit anti-mouse, clone 8C12, BD Pharmin-
gen, Franklin Lakes, NJ US) with streptavidin-A488 (Invitrogen)
and DAPI, or (ii) Lyve-1 (rabbit anti-mouse, 103-PA50AG,
ReliaTech, Wolfenbu¨ttel, Germany) and ER-TR7 (rat anti-
human/mouse, HM1086, Hycult biotech, Uden, The Nether-
lands) with secondary antibodies, A488-rabbit anti-mouse IgG and
A546-goat anti-rat,IgG, respectively (Invitrogen). Images were
taken on a Zeiss LSM 710 confocal microscope (Carl Zeiss Inc.,
Oberkochen, Germany) and in an upright Leica DM5500 (Leica
Microsystems, Bensheim, Germany). Images were processed on
ImageJ (v1.45b, NIH, Bethesda, MD).
Endocytosis assessment using flow cytometry
Splenocytes from naı¨ve C57Bl/6 female mice were isolated as
described above. Single-cell suspensions were re-suspended in RPMI
1640 medium supplemented with 10% FBS, 1% puromycin/
streptomycin (all from Invitrogen) and plated in 96 round well plates
(BD) to a final volume of 200 mL. Cells were treated with 225 mg of
either biotinylated NPs or control NPs (without biotin) and were
incubated at 37uC, 5% CO2 overnight. The following morning cells
were washed twice with chilled HBSS and stained with Live/Dead
Fixable Aqua (Invitrogen) for 20 min on ice. Cells were washed with
HBSS, 0.1% BSA and stained for extracellular markers (CD45,
B220, CD4, CD8a or CD11b, Ly6c and Ly6g) and streptavidin
A488 (1:500) in HBSS, 0.1% BSA, for 20 min on ice. Stained cells
were washed with HBSS and fixed with 2% PFA for 15 min on ice.
Afterwards, cells were washed twice with HBSS, 0.1% BSA, 0.5%
Saponin (permeabilization buffer) and stained with streptavidin-
A647 solution (1:500) in permeabilization buffer for 30 min on ice.
Finally cells were washed once with permeabilization buffer and re-
suspended in 200 mL HBSS, 0.1% BSA for flow cytometry.
Data analysis and visualization
All flow cytometry data were analyzed using FlowJo software
(v9.2, Treestar Inc., Ashland, OR). The gating strategy to identify
the major cellular subsets is depicted in Figures S2 and S3. NP
negative gates were set on cells derived from animals treated with
non-fluorescent NPs. Heat maps, which show median values of the
percentages of NP+ cell types at each timepoint and organ, were
generated using custom software in MATLAB (v7.11, Mathworks
Inc., Natick, MA). Assuming that the cellular NP association or
uptake is independent for each cell type, each cellular population,
was modeled with a Beta regression model using the betareg
package [24] within R (v2.13.1 R Foundation for Statistical
Computing) with logit as the link function for the means submodel
and square root link function for the variable precision submodel.
The mean response (% of NP+) was modeled as a combination of
the main effects and interactions of the route of administration,
time post inoculation and organ of interest, while the variable
precision as the combination of the main effects of the route of
administration, time post inoculation and organ of interest,
respectively. The full model was submitted according to the
formula:
% of NPz*Time  Administration Organ
TimezAdministrationzOrganj
The contribution of each factor was calculated as the log-
likelihood ratio (D) of the likelihood of each nested model (i.e the
full model without one of the factors) over the likelihood of the full
model: D~{2 ln
likelihood for nested model
likelihood for full model
 
. The signifi-
cance of each alternate model versus the full model was computed
using a Chi Square test. Statistical analysis was performed in
Graphpad Prism (v5.0c, Graphpad Software, Inc, La Jolla, CA
US) where appropriate.
Tumors
EL-4 lymphoma cells stably transfected with OVA (E.G7-OVA
cells, CRL-2113, ATCC, Manassas, VA) were cultured in RPMI
1640 medium supplemented with 10% FBS, 10 mM HEPES,
1 mM sodium pyruvate, 0.05 mM b-mercaptoethanol, 1%
puromycin/streptomycin (all from Invitrogen), and 0.4 mg/mL
G418 (PAA Laboratories GmbH, Pasching Austria). B16-F10
melanoma cells (CRL-6475, ATCC, Manassas, VA US) were
cultured in high glucose (4.5 g/L) DMEM (PAA Laboratories)
supplemented with 10% FBS, L-glutamine and 1 mM sodium
pyruvate (Invitrogen). Both cell lines were washed twice with saline
prior to inoculation. For the E.G7-OVA tumor model, mice were
anesthetized with isofluorane, shaved on the left shoulder
(dorsoanterior left lateral side), and inoculated subcutaneously
with 106 E.G7-OVA cells under the left shoulder blade. For the
B16-F10 model, mice were anesthetized with isofluorane, shaved
on the back, and inoculated subcutaneously with 56105 B16-F10
cells. Tumor volumes were estimated after measuring length (l),
width (w), and height (h), and assuming an ellipsoid geometry
(V~p=6
:l:w:h). When tumor volumes reached 100 mm2, mice
were administered i.d. with fluorescently labeled NPs in all four
footpads.
Results and Discussion
Nanoparticles accumulate in the blood and secondary
lymphoid compartments in antigen presenting cells
We evaluated the cellular distribution of 30 nm NPs 12 h after
i.d. footpad administration in all leukocytes (Figure 1a), further
dissecting the NP association using major markers within the
innate and adaptive immune compartments (Figures 1b and c,
Nanoparticle Monocyte Targeting
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with gating strategies shown in Figures S2 and S3). With regard to
leukocyte localization in different anatomical locations (Figure 1a),
NP+ leukocytes were found at high levels in the blood, kidneys and
spleen (863%, 662% and 361%, respectively; Figure 1a). This
distribution can be attributed partially to the poly(ethylene glycol)-
rich (PEGylated) corona and to their ultra-small size, which has
been demonstrated to bias NPs towards the spleen rather than the
liver [25].
We next considered which leukocyte compartments were
differentially targeted in the draining LNs, blood, and blood-
filtering organs (liver, kidney and spleen) (Figure 1b, c). Consistent
with lymphatic uptake after i.d. administration, NP uptake in the
draining LNs was observed, with the popliteal LN (the sentinel LN,
i.e. the LN that is closer to the hindlimb injection site than inguinal
LN, or the axillary or brachial are to the forelimb injection site)
collecting the injected NPs most efficiently. In the draining LNs,
NPs associated at high levels with immature lymphoid dendritic cells
(DCs, CD11c+CD11b2I/Ab2; 8.5619.9%) and B cells (B220+;
7.365.6%), as well as other phagocytic cell populations, such as the
immature myeloid DCs (CD11c+CD11b+I/Ab2; 5.7619.8%),
cross-presenting DCs (CD11c+CD8a+I/Ab+; 36616%) and med-
ullary (LN) or red pulp (spleen) macrophages (CD11c+CD11b+F4/
80+I/Ab2; 70620%).
Those NPs that passed through the lymphatic circulation
entered the bloodstream through the thoracic duct. In the blood,
circulating NPs populated the entire compartment of circulating
(blood) and resident (LNs and spleen) monocytes (CD11b+
GR1+SSClowF4/80+).
Once in the blood, the NPs were subject to clearance in the
blood-filtering organs. The spleen retained a similar cell association
pattern as the blood, dominated by monocytes and medullary/red
pulp macrophages, with the pattern less intensively followed in the
liver and lungs (Figure 1c). In contrast, NP association patterns with
cell types in the kidney were distinctly different from those of the
spleen, liver, and lungs. In particular, NPs were associated strongly
with activated (CD25+) CD4+ T cells in the kidneys (1069%)
(Figure 1b); although the reasons for this are unclear. Strikingly,
throughout all the organs evaluated, NPs were found to be predom-
inantly cleared by the mononuclear phagocytic system (MPS) after
12 h (Figure 1c).
These results were particularly interesting for immunomodula-
tory targeting, including for vaccination. Macrophage subsets have
different roles in vaccination, where subcapsular macrophages form
a primary barrier against the spread of infectious agents [18] and
furthermore start the antigen transfer chain towards follicular
dendritic cells for effective B cell responses [26,27]. Medullary
macrophages, which were very effectively targeted by the NPs in the
draining LNs as well as the red pulp macrophages in the spleen, also
form a clearance mechanism for particles that enter these organs
[28], although less efficient than DCs for T cell priming [29]. DC-
specific targeting, which is more interesting for vaccination [30–32],
was most effective in the draining LNs and spleen. Both immature
myeloid and lymphoid DCs have migratory capacities and can
process antigens to prime T cell responses [33]. Mature myeloid
DCs, migrating under steady-state conditions, may derive from the
periphery [34,35]. At 12 h post i.d. immunization, we see these
populations positive for NPs, especially in the popliteal LN.
Moreover, cross-presenting DCs (CD11c+CD8a+I/Ab+) resident
in the LNs as well as the spleen were targeted; this cell population is
particularly interesting for vaccine applications in that it is capable
of priming CD8+ T cell responses [36] by loading exogenous
antigen, e.g. nanoparticle-bound antigen, onto MHC I. This
observation is consistent with our previous studies of MHC I-
binding peptide antigens conjugated to NPs inducing strong
expansion of the antigen-specific CD8+ T cell compartment [8],
indicating that cross-presentation of the antigen had taken place.
Figure 1. Nanoparticle biodistribution in tissues and cells show secondary lymphoid organ accumulation. Heat maps show
nanoparticle (NP)-positive percentages of each indicated cell type in lymph nodes (LN) or blood-filtering organs 12 h after i.d. injection as analyzed by
flow cytometry. (a) Overall leukocyte (CD45+) in different tissues. leukocyte subpopulations with (b) low to medium levels (0–15%) or (c) high levels
(up to 98%) of NP accumulation. B cells: B220+, T cells: (CD3e+ then CD4+CD25+, CD4+CD252, CD8+), TCRcd: CD3e+CD42CD82 TCRcd+, immature
myeloid dendritic cells (DCs): CD11c+CD11b+I/Ab2, immature lymphoid DCs: CD11c+CD11b2I/Ab2. (c) Granulocytes: CD11b+GR1highSSChigh,
monocytes: CD11b+GR1lowSSClowF4/80+, mature myeloid DCs: CD11c+CD11b+I/Ab+, CD11c+CD8a+I/Ab+, CD11c+CD11b2I/Ab+, medullary macrophag-
es (MØ): CD11b+F4/80+. Draining LNs are indicated by Ax: axillary, Br: brachial, In: inguinal, Po: popliteal; Sp: spleen, Bl: blood, Kd: kidneys, Li: liver, Lu:
lungs. Heatmap color scales indicated on the right. Refer to gating strategies in Figures S2 and S3.
doi:10.1371/journal.pone.0061646.g001
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The ability to target B and T lymphocytes in the LNs and spleen
may be of value in immunomodulation. Direct modulation of B
and T cells, if more efficiently targeted, may be of interest in the in
vivo implementation of the auto-feedback of T cell activation by
particles cross-linked to T cells previously shown for ex-vivo
activation and adoptive transfer [11].
As a point of comparison with biological particles, we examined
the biodistribution of virosomes derived from A/Singapore/6/86
influenza virus, which have been shown to produce effective
antibody titers in clinical trials [37]. In stark contrast to the NPs,
virosomes were cleared predominantly in the liver and were
associated with T cells there (Figure S4). They also targeted,
although to a much lesser extent, monocytes, medullary macro-
phages, and immature lymphoid and myeloid DCs in the LNs
(Figure S4). Such predominantly hepatic uptake of the virosomes
has been documented earlier [38], while the NPs largely avoided
clearance by the liver and accumulation in the spleen. This was
likely due to the smaller NP size (,50 nm) and PEGylated corona
[25]. It is well established that biomaterials such as PEG attribute
‘‘stealth-like’’ characteristics and therefore ensure long-circulation;
they are opsonized by the MPS as they trigger the alternative
complement pathway [39]. Most of the studies that address the
biodistribution of fully or partially synthetic particulates focus either
at the organ level [40] or examine only the major immune cell
populations [13,16]. While earlier studies have reported that
nanoparticles are selectively cleared by the MPS [16], our studies
of APC subtype distributions show that NPs have a unique and
distinct association pattern, with a tendency to accumulate in cells of
myeloid origin in lymphoid tissues rather than in the lymphocyte
populations of the liver.
Intradermal nanoparticle administration favors rapid
myeloid cell accumulation
While previous studies have compared immune responses to
various vaccination routes, especially with more recent i.d. delivery
technologies such as microneedles [41], it is still unclear how i.d. vs.
i.m. routes of administration influence the efficiency of nanoparti-
culate delivery to various cell compartments as well as subsequent
immune responses [3,40,42]. We observed that i.m. administration
resulted in lower bioavailability in blood as compared to i.d. (54%
vs. 83%, respectively; Figure 2a). We then compared NP kinetics
and cellular distribution in the blood and the secondary lymphoid
organs after i.d. vs. i.m. administration (Figure 2b). Overall, NPs
administered i.d., but not i.m., extensively associated with
leukocytes in the popliteal LN within the first hour (563% vs.
264% respectively in the popliteal LN); in the other LNs, peak NP
association was observed after 6 d (Figure 2b first panel). B and T
cells showed peak association after 24 h for both routes of
administration, and both compartments showed stronger associa-
tion after i.d. administration compared to i.m. Since T and B cells
accounted for the majority of the leukocytes within the LNs, the
higher percentages of NP+ leukocytes on day 6 was attributed
mainly to T cells.
In comparing APC subsets, as was seen in Figure 1c, major
populations of the MPS were found to be positive for NPs.
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Figure 2. Nanoparticles target lymph node dendritic cells
better after i.d. vs. i.m. delivery. (a) Blood concentrations of Dy649-
labeled NPs after i.v., i.m. and i.d. administration. (b) Heat maps
representing the median percentage of NP+ cells for indicated cell
populations. Note that maxima vary from 10% in total leukocytes to
100% in monocytes. P values were computed by comparing the
adjusted means of each organ between i.d. and i.m. for each cell type
with a two-tailed Student’s t-test. (c) Importance of route of
administration for each cellular subtype. The log-likelihood ratio
represents the likelihood of the alternate model, i.e. the model without
taking account the route of administration, over the likelihood of the
full factorial model. P values were computed using the Chi Square test
between the alternate model and the full model for each population.
For 144 h, n= 2, for all else, n$4. Leukocytes: CD45+, mature myeloid
DCs: CD11c+CD11b+I/Ab+, cross-presenting DCs: CD11c+CD8a+ I/Ab+,
immature myeloid DCs: CD11c+CD11b+I/Ab2, immature lymphoid DCs:
CD11c+CD11b2I/Ab2, medullary/red pulp (RP) macrophages (MØ):
CD11b+F4/80+, monocytes: CD11b+GR1midSSClowF4/80+, granulocytes:
CD11b+GR1highSSChigh, T cells: CD3e+, B cells: B220+. Draining lymph
nodes are indicated by Ax: axillary, Br: brachial, In: inguinal, Po:
popliteal; Sp: spleen. *p#0.05, **p,0.01, ***p,0.005.
doi:10.1371/journal.pone.0061646.g002
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Consistent with the overall leukocyte association, i.d. delivery
resulted in early associations in sentinel skin-draining LNs nearly
regardless of the cell population studied. Throughout the first 12 h
post-inoculation (and only in the popliteal LN), the CD8a+ DCs
that are notable for their efficient cross-presentation capacity
[43,44] internalized NPs to a higher extent after i.d. administra-
tion (1 h: 40610%, 6 h: 40620%, 12 h: 40620%) than after i.m.
(1 h: 161%, 6 h: 20620%, 12 h: 30620%). In the initial time
points (6 h) after i.d. administration, immature myeloid and
lymphoid DCs showed enhanced NP uptake within the axillary
LN (60630% and 20620% respectively) and popliteal LN
(80620% and 1462% respectively), while accumulation was
pronounced only after 12 h of i.m. administration (80630%,
10620%). The peak uptake of mature myeloid DCs was not
affected by the route of administration, reaching a maximum
80610% for both i.d. and i.m. administration in the popliteal
node (Figure 2b).
Within the window of 12–24 h after injection, nearly all of the
medullary macrophages were associated with NPs in the draining
LNs nodes irrespectively of the administration route (Figure 2b, 8th
panel). This is consistent with the mode of NP entry in the LN,
where smaller nanoparticles flow to the LN thus associating with
medullary APCs [13]. Granulocytes were minimally affected by
the route of administration, with the pattern of association being
less intense and delayed than for the other cells of the MPS. Most
strikingly, monocytes were NP+ in all organs, including the spleen,
as early as 6 h and until 24 h. However, at 6 days, monocytes were
no longer NP-associated.
A majority of NPs pass the LNs around the subcapsular sinus
and arrive in the spleen after entering the blood circulation,
irrespective of administration route. Thus, NP association with all
cell types in the spleen was delayed relative to that in the LNs
(Figure 2b), although the kinetics of splenic targeting via these two
routes were similar (Figure 2b). For all cell populations in the
spleen, i.d. administration led to equal or greater cell targeting
compared to i.m. (Figure 2b), consistent with the greater
bioavailability (Figure 2a). As in the LNs, NP distribution in the
spleen after 24 h was dominated by the association with B cells
(i.d.: 663% vs. i.m.: 3.260.7) and T cells (i.d.: 761% vs. i.m.:
562%) due to their dominance in overall cell numbers. Among
the other cell types, monocytes, medullary/red pulp macrophages,
and granulocytes were particularly well-targeted in the spleen
(Figure 2b, panels 8–10).
To better understand the relative importance of the adminis-
tration route for targeting each cell type, we built a statistical
regression model and partitioned the entire cellular distribution
data set into a hierarchical binary tree [24] according to the
significance of each subset, comparing the route of administration
(Figure S5). Within the LNs, the model demonstrated that route of
administration is significant only for the sentinel (i.e., popliteal and
axillary) LNs (sentinel draining LNs) for NP association, confirm-
ing the physiology and anatomy of lymphatic drainage from the
skin (Figure S5). Accordingly, the route of administration did
matter as much for particular cell targeting in the downstream
LNs (i.e.,brachial and inguinal). To further confirm the impor-
tance of the route of administration on the specific cellular
compartments targeted, we formulated an alternate regression
model in which the factor of the administration was neglected, and
we compared it with the full model for each cell type (Figure 2c).
The importance of the i.d. administration, quantified as the log-
likelihood ratio of the alternate model over the full model, was
pronounced within the overall leukocyte population, the DC
subpopulations, monocytes and granulocytes, while it was
indifferent for the medullary macrophages, most likely due to
their spatial location in the secondary organs. This, in conjunction
with blood bioavailability results (Figure 2a), emphasized that
superiority of the i.d. route over i.m. for targeting NPs to the LNs,
blood, and spleen. Together, these findings highlight the
significance of the i.d. route for effective delivery to immature
and cross-presenting APCs in sentinel LNs.
Nanoparticle trafficking to the LN relies on lymphatic
drainage
The early (#6 h) association of NPs with LN-resident leukocytes
suggests that lymphatic drainage from the administration site is a
key determinant in uptake and distribution. To confirm this
supposition, we inoculated i.d. the same amount of fluorescently
labeled NPs in transgenic mice that lack peripheral lymphatics in
the dermis. NPs injected into K14-VEGFR-3-Ig mice, which lack
dermal lymphatic capillaries due to soluble VEGFR-3 secretion by
keratinocytes [22,45], were not present in the blood even 24 h
after i.d. administration (Figure 3a). We observed minimal NP
association in the draining LN and the spleen, as determined by
measurements on leukocytes, monocytes, DCs and B cells
(Figure 3b), among other compartments (data not shown).
Therefore, drainage via the dermal lymphatics is essential to
target cells in secondary lymphoid organs or blood after i.d.
administration.
Upon entry into the initial lymphatics, we observed that NPs
entered the LN from the afferent lymphatics as expected.
However, rather than remaining in the subcapsular sinus and
bypassing the LN interior (Figure 3c, red arrows), a substantial
amount of NPs were seen entering the conduits to the medulla
(Figure 3c, M), diverting from the B cell follicle (FO) or cortex
regions. When stained for the stromal cell marker ERTR-7 and
the lymphatic marker LYVE-1, which indicate the architectural
pattern of drainage within the LN [46], the fluorescent NPs were
mainly confined within the LYVE-1+ structures of the lymphatics
(Figure 3d) and populated the LN medulla. In the spleen after
24 h, NPs had entered the organ from the central arteriole
(Figure 3e and f, white arrowhead) and were found to populate the
entire red pulp, reaching the marginal zone without penetrating
the B cell follicles of the white pulp (Figure 3e and f), and were
retained in the subcapsular space (Figure 3e).
These results demonstrate that the early cell association of the
NPs after i.d. injection could be attributed to the initial drainage of
NPs from the dermis into the lymphatics, and that the cell
distribution within the LN was consistent with the cells that
populate the medulla of LNs. For those NPs that entered the
systemic circulation, the cell distribution within the spleen was
consistent with entry from the central arteriole [47]. This
anatomical distribution is consistent with the flow cytometric
analysis of cell subset associations presented in Fig. 1 and 2b:
namely, immature DCs and medullary macrophages are resident
subpopulations, located in the medulla of LNs and around the
marginal zone (MZ) in the spleen [47]; monocytes are predom-
inantly resident in the bone marrow, but are also resident in the
subcapsular red pulp of the spleen, from where they are deployed
under inflammatory conditions [48]. Taken together, i.d. admin-
istration enhances NP association with monocytes and to an extent
with antigen-presenting populations within the LN and spleen,
following the pattern of lymphatic drainage.
Intracellular vs. extracellular association of nanoparticles
In the in vivo kinetic study described above, we observed by flow
cytometry that over the time course of observation, monocytes and
granulocytes consistently displayed a distinct population shift,
while B cells and T cells exhibited only a partial increase in
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fluorescence in NP-Dy649 channel with the main population not
shifting (fluorescence for monocytes and B cells shown in
Figure 4a). As we have previously shown that NPs are taken up
by DCs via macropinocytosis [8], we asked whether monocytes,
granulocytes, B cells, and T cells that associated with NPs in vivo
followed the same mode of endocytosis. Specifically, using a multi-
step extra- and intra-cellular streptavidin staining with two
different fluorophores, we asked whether biotinylated NPs
incubated with splenocytes in vitro were located extracellularly or
intracellularly. We noted that B and T cells displayed a
predominant shift only in the fluorescent channel related to the
extracellular staining (Figure 4b, corresponding to double positive
for streptavidin AF488 as well as AF647). On the other hand, NPs
were found both externally and internally in the monocytic, while
less amount of fluorescence was observed to co-localize within the
granulocytic compartments. This confirmed that NPs were indeed
endocytosed by monocytes and granulocytes (Figure 4b), while
they stay predominantly on the exterior of T and B cells,
associated with the plasma membrane. Surface association of lipid-
based nanoparticles with T cells has been observed by others,
mediated for example by cell-surface thiols from unpaired cysteine
residues [49].
To further determine whether NPs were macropinocytosed by
monocytes and granulocytes, we performed uptake studies of NPs
using a phosphatidylinositol 3-kinase inhibitor of macropinocytosis
(LY249004), which we have previously shown to block macro-
pinocytosis in DCs [8]. Macropinocytosis was reduced in an
inhibitor concentration-dependent manner (Figure 4c). We
observed that CD11b+Ly6c+ monocytic myeloid cells took up
fewer NPs, while CD11b+Ly6cmidLy6g+ polymorphonuclear
(Figure 4c) as well as B and T cells (data not shown) were not
affected by LY249004 treatment. Thus, the biodistribution of NPs
Figure 3. Lymphatic drainage is required for nanoparticle targeting of the lymph node and spleen after i.d. administration. (a)
Bioavailability of Dy649-nanoparticles (NPs) in the blood compartment after i.d. administration in mice that lack peripheral lymphatics (K14-VEGR-3-
Ig) and their wild type littermates. VH: vehicle control (non-fluorescently labeled NPs). Two-way repeated measures ANOVA followed by Bonferroni
post test. (b) Comparison of NP+ association as assessed by flow cytometry in the brachial lymph node (LN) and the spleen 24 h post-i.d.
administration. n = 4 *p#0.05, ***p#0.005. (c) 9 mm thick section of a Dy649-NP (red) draining wild type popliteal LN stained with nuclei (DAPI, blue).
Scale bar, 200 mm. (d) 9 mm thick section of the NP-Dy649 (red) draining wild type brachial LN 12 h after i.d. administration, stained for lymphatic
endothelium (LYVE-1, green), the T cell zone stroma (ERTR7, white). Scale bar, 40 mm. (e) 40 mm section of the wild type anterior spleen stained with
DAPI (blue) and NP-Dy649 (red) shows NP accumulation in the red pulp (RP) and the marginal zone (MZ), as well as surrounding the B cell follicles
(FO). Scale bar, 300 mm. (f) Enlarged region of the central arteriole of the spleen (white filled arrow) (i) immunofluorescence image (NP-Dy649, red and
DAPI, blue). (ii) Hematoxylin & eosin staining of the same section of the spleen; dark blue FO, purple red pulp and pink blood vessels. Scale bar,
100 mm.
doi:10.1371/journal.pone.0061646.g003
Nanoparticle Monocyte Targeting
PLOS ONE | www.plosone.org 7 April 2013 | Volume 8 | Issue 4 | e61646
to detailed cell subsets also could be further separated into NP-
internalizing and NP-associating cell types, a factor that
determines the fate of the delivered payload and its effects on
the cells [11].
Nanoparticles target MDSCs in secondary lymphoid
organs and tumors
Based on the observation that NPs were found in nearly all cells
of the monocytic compartment (Figure 1b), and given that
monocytes play a pivotal role in both inflammatory (as in
myocarditis) [48] and immunosuppressive [50,51] phenotypes
(e.g., myeloid derived suppressor cells, MDSCs), we reasoned that
the i.d. route of administration of NPs could be used to target
immunosuppressive monocytes with therapeutic applications in
mind. Cells of the monocytic origin, phenotypically characterized
as CD11b+Ly6gmidLy6c+ (or CD11b+GR1+SSClowF4/80+), derive
from the bone marrow. They populate the blood compartment,
accumulate in chronic inflammatory sites such as the tumor
microenvironment [52], and traffic to secondary lymphoid organs,
where, depending on the appropriate context, they exert their
Figure 4. Monocytes internalize nanoparticles via macropinocytosis while B and T cell associate externally. (a) Representative flow
cytometry plots of in vivo NP-Dy649+ uptake kinetics after intradermal administration: monocytes (CD11b+GR1midSSClowF4/80+) and B cells (B220+) in
the spleen. (b) Characteristic flow cytometry plots of biotinylated nanoparticle (NP-biotin) association with splenic (B, CD4, and CD8 cells) and bone
marrow (CD11b+Ly6c+ and CD11b+Ly6g+) cells after 12 h incubation in vitro. To distinguish surface-associated- from internalized-NPs, cells were
incubated before permeabilization with streptavidin-A488 (for extracellular association) and after permeabilization with streptavidin-A647 (for
intracellular uptake). (c) Percentage of fluorescently labeled NPs (NP-Dy649) taken up by bone marrow cells as a function of the PI3K inhibitor
(Ly294002) concentration. Bone marrow cells were incubated with increasing concentrations of Ly294002 (maximum 50 mM) for 459 prior to the
addition of NP-Dy649 for 12 h. Cells were subsequently stained and analyzed by flow cytometry. Open circles: CD11b+Ly6c+, filled squares:
CD11b+Ly6g+, continuous line: vehicle control (VH, DMSO) for CD11b+Ly6c+, dashed line: VH for CD11b+Ly6g+.
doi:10.1371/journal.pone.0061646.g004
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suppressive function. It has been shown that tumors can elicit
significant amounts of MDSCs in the spleen [51] and in the tumor
microenvironment [50,53] in humans and mice. As MDSCs can
suppress self or induced anti-tumoral responses in the microen-
vironment by secreting a plethora of biomolecules that either block
T cell activation and proliferation or act upon DCs and macro-
phages to bias them towards tolerance-inducing APCs [54],
MDSCs are significant targets for immunomodulation. Thera-
peutically, it was recently shown that systemic delivery of nano-
particles leads to selective uptake by inflammatory monocytic
populations accumulating in atherosclerotic lesions, which can be
reversed in mice by delivering CCR2-silencing short interfering
RNA [55,56].
To address whether our NPs could be used to target MDSCs in
tumor models, we used E.G7-OVA or B16-F10 cell lines grafted
into immune competent C57Bl/6 mice. When tumors reached
approximately 100 mm2, mice were administered i.d. fluorescently
labeled NPs. 12 h after administration, we assessed the presence of
MDSCs and their association with NPs in the tumor microenvi-
ronment, LNs and the spleen by flow cytometry (Figure 5a–c for
E.G7-OVA tumors and Figure S6 for B16-F10 tumors). Interest-
ingly, the majority of the monocytic MDSCs (CD11b+Ly6-
g2Ly6c+) in the tumor-draining LN (TDLN) (8761%), spleen
(7963%) and tumor microenvironment (7768%) were NP+
(Figure 5a,d). The fact that monocytes continuously traffic from
the secondary lymphoid organs to the site of inflammation [57] is
consistent with our measurements of similar frequencies of NP+
monocytic MDSCs in these three organ sites. In contrast, the
granulocytic MDSCs (CD11b+Ly6g+Ly6cmid) populating the
TDLN displayed higher association (3567%) than the non-TDLN
(1662%), spleen (1063%) and tumor (963%) (Figure 5a,e). This
further highlights the importance of lymphatic drainage to target
not only circulating monocytic MDSCs but also to focus targeting
of polymorphonuclear MDSCs in TDLNs. With this data, we
conclude that NPs delivered through the i.d. route efficiently target
local and systemic MDSCs by exploiting lymphatic drainage.
Conclusions
Understanding the trafficking distribution of nanoparticles to
specific immune cell populations in the secondary lymphoid tissues
and blood filtering organs is of high importance, especially when
dealing with formulations that carry potent payloads, such as
chemotherapeutics and adjuvants. Here, we showed that that fully
synthetic 30 nm Pluronic-stabilized poly(propylene sulfide) NPs
accumulate in the draining LN and spleen, but not in the liver. We
also highlighted that lymphatic flow is crucial for NP drainage,
both in the i.d. injection site and in the LN itself. At the level of the
cellular population, we showed NPs localized to the myeloid
compartment, consistent with their phagocytic ability, including
DCs in the LN and the spleen, demonstrating a bias towards
medullary macrophages and mature myeloid DCs. Of particular
interest in vaccination, among the DCs efficiently targeted were
CD8a+ DCs that are efficient at cross-presentation. Among the
myeloid populations efficiently targeted were monocytes, both in
the LN and spleen, as well as MDSCs in the tumor sites. Knowing
the exact populations and timing of NP targeting will greatly
accelerate the design of smarter, more efficient drug delivery and
vaccine platforms while minimizing the risk of side-effects.
Supporting Information
Figure S1 Labeled nanoparticles were free of unconju-
gated dye. (a) Nanoparticle conjugation scheme with Dy649-
maleimide. (b) Characteristic analytical HPLC elution profiles of
nanoparticles before and after dialysis. NP conjugated with Dy649-
maleimide were injected in a size exclusion column (ID = 3 mm,
L = 300 mm) packed with SepharoseH CL6B and analyzed in a
fluorescent detector (excitation = 655 nm, emission = 685 nm).
(EPS)
Figure S2 Gating strategy of the innate immune cell
compartment. Characteristic flow cytometry analysis of a spleen
injected with control nanoparticles (black) or Dy649-nanoparticles
(blue). Populations described within the manuscript are highlight-
ed below. (a) Cross-presenting dendritic cells: CD11c+CD8a+; (b)
medullary/red pulp macrophages (MØ): GR1lowSSChighCD11b+
F4/80+; (c) granulocytes: CD11b+GR1highSSChigh; (d) monocytes:
CD11b+GR1midSSClowF4/80+; (e) mature myeloid DCs: CD11c+
CD11b+I/Ab+; (f) immature myeloid DCs: CD11c+CD11b+I/
Ab2; (g) immature lymphoid DCs: CD11c+CD11b2I/Ab2.
(EPS)
Figure S3 Gating strategy of the adaptive immune cell
compartment. Characteristic flow cytometry analysis of a spleen
injected with control nanoparticles (black) or Dy649-nanoparticles
Figure 5. Nanoparticles are taken up by MDSCs in draining nodes, spleen and tumor.Mice were inoculated subcutaneously with 106 E.G7-
OVA thymoma cells underneath the left shoulder blade (dorsoanterior left lateral side). After tumors reached 100 mm3, mice were injected with
Dy649-labeled nanoparticles (NPs). Flow cytometry plots illustrating targeting of (a) monocytic (MO) MDSCs and (b) polymorphonuclear (PMN)
MDSCs in the tumor draining lymph node (TDLN), the spleen and the tumors. (c) Three-dimensional flow-cytometry representation of the MDSC
compartment (MO and PMN) of the tumor. Comparison between different organs of interest of the (d) MO-MDSCs and (e) PMN-MDSCs
subpopulation accumulating NPs. One-way ANOVA followed by Bonferroni post test. n = 3 *p#0.05, **p#0.01. Tu: Tumor; Sp: Spleen.
doi:10.1371/journal.pone.0061646.g005
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(blue). (a) CD45+ cells were separated to (b) B cells and T cells
based on the expression of CD3e and B220, respectively. T cell
gate was further split up to CD4+, (c) CD8a+ and double negative
T cells. CD4+ cells were characterized by their CD25 expression;
(d) CD25+ and (e) CD252. Double negative T cells were separated
based on (f) TCRcd+ cells.
(EPS)
Figure S4 Tissue and cell biodistribution 12 h after
intradermal administration of virosomes show prefer-
ential accumulation in the liver. Dy649-NHS labeled L-a-
phosphatidylethanolamine was incorporated into the beta-propio-
lactone inactivated-, nucleocapsid removed-A/Singapore/6/86
influenza virus and injected intradermally into C57Bl/6 mice.
After 12 h, heat maps show that virosomes (VSs) were found
preferentially associated with (a) leukocytes (CD45+) in the liver
(1268%). (b) B cells: B220+, T cells: (CD3e+ then CD4+CD25+,
CD4+CD252, CD8+), TCRcd: CD3e+CD42CD82 TCRcd+,
immature myeloid dendritic cells (DCs): CD11c+CD11b+I/Ab2,
immature lymphoid DCs: CD11c+CD11b2I/Ab2. (c) granulo-
cytes: CD11b+GR1highSSChigh, monocytes: CD11b+GR1lowS-
SClowF4/80+, mature myeloid DCs: CD11c+CD11b+I/Ab+,
CD11c+CD8a+I/Ab+, CD11c+CD11b2I/Ab+, medullary macro-
phages (MØ): CD11b+F4/80+. Draining lymph nodes are
indicated by Ax: axillary, Br: brachial, In: inguinal, Po: popliteal;
Sp: spleen, Bl: blood, Kd: kidneys, Li: liver, Lu: lungs. Heatmap
color scales indicated on the right. Several leukocyte subsets
displayed (a, b) low to medium levels (0–15%) or (c) high levels (up
to 98%) of association with VSs.
(EPS)
Figure S5 Sentinel lymph nodes and the spleen are most
affected by the route of administration. (a) Hierarchical
binary tree of all NP+ cellular compartments from the cell
compartment kinetic analysis, comparing all the draining
lymphoid organ of interest and the route of administration.
Analysis was performed in the statistical analysis package R, using
the betatree regression model. (b) Schematic representation of the
location of the secondary lymphoid organs draining the injection
site. Sentinel nodes: axillary (Ax) and popliteal (Po); non-sentinel
nodes: Brachial (Br) and Inguinal (In); Spleen (Sp).
(EPS)
Figure S6 Nanoparticles naturally target MDSCs in
tumor-draining lymph nodes, spleen and tumor. Mice
were inoculated with 106 B16-F10 melanoma cells, and when
tumor volumes reached 100 mm3, mice were injected intrader-
mally with fluorescently labeled nanoparticles (NPs), 12 h after NP
administration the spleen and tumor were harvested, stained and
analyzed by flow cytometry. Histograms illustrating targeting of (a)
monocytic (MO) MDSCs and (b) polymorphonuclear (PMN)
MDSCs in the spleen and the tumors.
(EPS)
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